Metabolic restaging of hepatocellular carcinoma using whole-body 18F-FDG PET/CT

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 1, Issue 1

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

665

HTML

5867

Figures (1-4)

821

Tables (1-2)

709

Sum=8062

Oct 31, 2009 (publication date) through Oct 26, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Hepatol. Oct 31, 2009; 1(1): 90-97
Published online Oct 31, 2009. doi: 10.4254/wjh.v1.i1.90

Table 1 Patients' features

Clinical characteristics	Data
Mean age (yr)	51.6 (range 27-81 yr)
Gender
Males	21
Females	4
Prior therapy
TACE	6
Liver resection	9
TACE after surgery	8
TACE + RFA or PEI	2
Unexplained AFP increase after treatment	14
Mean time from treatment to recurrence	11.5 mo
Mean time after treatment to PET/CT exam	10 d - 12 yr; mean 13 mo
Mean follow up time after PET/CT exam	3 mo - 21 mo; mean 12 mo

Table 2 Characteristics of recurrent HCC in 17 true positive patients

Characteristics	n
Intrahepatic recurrence	8
Intrahepatic recurrence and extrahepatic metastases	5
Extrahepatic metastases without intrahepatic recurrence	4
Single intrahepatic recurrence	7
Multiple intrahepatic recurrence	8
Lung	4
Bone	1
Omentum and mesentery	3
Retroperitoneal lymph nodes	2
Adrenal	1

Citation: Sun L, Guan YS, Pan WM, Luo ZM, Wei JH, Zhao L, Wu H. Metabolic restaging of hepatocellular carcinoma using whole-body ¹⁸F-FDG PET/CT. World J Hepatol 2009; 1(1): 90-97
URL: https://www.wjgnet.com/1948-5182/full/v1/i1/90.htm
DOI: https://dx.doi.org/10.4254/wjh.v1.i1.90